Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §102 only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POPA, ILEANA | 1 | 21.0% | +14.9% |
| PORTER, JR, GARY A | 1 | 68.9% | +25.2% |
| STOICA, ELLY GERALD | 1 | 66.5% | +22.9% |
| KOSTURKO, GEORGE W | 1 | 54.2% | +49.1% |
| MARVICH, MARIA | 1 | 54.7% | +27.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18471761 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | POPA, ILEANA | 50d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18471761 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | POPA, ILEANA | 50d overdue |
| 18250532 | DIRECTIONAL AND SCALABLE ELECTRODE ARRAY | PORTER, JR, GARY A | 16d overdue |
| 18027993 | DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS | STOICA, ELLY GERALD | 11d overdue |
| 17926214 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | KOSTURKO, GEORGE W | 8d overdue |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | MARVICH, MARIA | 54d |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 3796 | 1 |
| 1647 | 1 |
| 1621 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18471761 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | POPA, ILEANA | 1633 | §103 | Final Rejection | 50d overdue | Pending | Sep 21, 2023 |
| 18250532 | DIRECTIONAL AND SCALABLE ELECTRODE ARRAY | PORTER, JR, GARY A | 3796 | §103 | Final Rejection | 16d overdue | Pending | Apr 25, 2023 |
| 18027993 | DISCOVERY AND USE OF IMMUNOGENIC PEPTIDES FOR THE TREATMENT AND PREVENTION OF CANCERS | STOICA, ELLY GERALD | 1647 | §102 | Non-Final OA | 11d overdue | Pending | Mar 23, 2023 |
| 17926214 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | KOSTURKO, GEORGE W | 1621 | §103 | Non-Final OA | 8d overdue | Pending | Nov 18, 2022 |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | MARVICH, MARIA | 1634 | Other | Final Rejection | 54d | Pending | Jun 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial